TG Therapeutics to Participate in the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/20/22
Will TG Therapeutics (TGTX) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 05/02/22
TG Therapeutics to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology ConferenceGlobeNewsWire • 04/26/22
TG Therapeutics Retracts FDA Request For Ublituximab / Ukoniq Combo In Blood CancersBenzinga • 04/18/22
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLLGlobeNewsWire • 04/15/22
TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual MeetingGlobeNewsWire • 04/06/22
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual MeetingGlobeNewsWire • 04/04/22
TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee MeetingGlobeNewsWire • 03/10/22
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual MeetingGlobeNewsWire • 03/04/22
FDA Pushes TG Therapeutics' Ublituximab / Ukoniq Combo Therapy Applications In Blood Cancer SettingsBenzinga • 03/03/22
TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLLGlobeNewsWire • 03/03/22
TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial ResultsGlobeNewsWire • 03/01/22
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumGlobeNewsWire • 02/25/22
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business UpdateGlobeNewsWire • 02/24/22
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumGlobeNewsWire • 02/15/22